2012
Neurosurgical Approach
Moliterno JA, Patel TR, Piepmeier JM. Neurosurgical Approach. The Cancer Journal 2012, 18: 20-25. PMID: 22290253, DOI: 10.1097/ppo.0b013e3183243f6e3.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingTumor cellsResonance imagingAggressive surgical resectionAggressive tumor removalFunctional brain tissueFrequency of seizuresExtent of resectionGoal of surgeryInfiltrative tumor cellsPreferred initial stepFunctional magnetic resonance imagingProliferative tumor cellsAdjuvant therapyAggressive resectionSurgical resectionTumors recurCritical cortical regionsNeurologic impairmentTumor burdenProspective studyTumor resectionTumor removalInfiltrative tumorsMalignant gliomas
2007
Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group
Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK. Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group. Journal Of Clinical Oncology 2007, 25: 837-844. PMID: 17327604, DOI: 10.1200/jco.2006.08.1117.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryIntracerebral convection-enhanced deliveryCintredekin besudotoxRecurrent malignant gliomaMalignant gliomasGlioblastoma multiformeMedian survivalCatheter placementTumor resectionInfusion durationProcedure-related adverse eventsFavorable risk-benefit profilePhase I clinical studyBetter drug distributionDirect intracerebral deliveryOptimal drug distributionOverall median survivalPortion of patientsRisk-benefit profileDevastating brain tumorDrug distributionAdverse eventsHigh tissue concentrationsIntracerebral deliveryTumor necrosis
2006
Diffusion MRI in the early diagnosis of malignant glioma
Baehring JM, Bi WL, Bannykh S, Piepmeier JM, Fulbright RK. Diffusion MRI in the early diagnosis of malignant glioma. Journal Of Neuro-Oncology 2006, 82: 221-225. PMID: 17029014, DOI: 10.1007/s11060-006-9273-3.Peer-Reviewed Original ResearchConceptsDiffusion-weighted imagingMalignant gliomasApparent diffusion coefficient (ADC) mapsCentral necrosisNodular enhancing lesionsResultsOf 89 patientsTimely definitive diagnosisSubset of patientsClinical decision-making processBrain Tumor CenterFurther tumor growthHigh-grade gliomasTypical radiographic presentationTime of imagingSubset of casesLow signal intensityDiffusion coefficient mapsConclusionsThe diagnosisDefinitive diagnosisEloquent areasEnhancing lesionsMass lesionRadiographic presentationRim enhancementInclusion criteria
2005
Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas
Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT. Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas. Cancer Research 2005, 65: 6726-6733. PMID: 16061654, DOI: 10.1158/0008-5472.can-05-0585.Peer-Reviewed Original ResearchConceptsBEHAB/brevicanHigh-grade gliomasMalignant gliomasBrain tumorsNew potential therapeutic targetsPrimary brain tumorsNormal adult brainDeadly brain tumorCentral nervous systemPotential therapeutic targetLow-grade gliomasHuman malignant gliomasNew therapeutic strategiesPathologic courseSimilar histologyBenign gliomasAdult brainTherapeutic strategiesDiffuse invasionTherapeutic targetGlioma progressionNervous systemInvasive abilityBrain tissueGliomas
2004
Non-enhancing de novo glioblastoma: report of two cases
Cohen-Gadol AA, DiLuna ML, Bannykh SI, Piepmeier JM, Spencer DD. Non-enhancing de novo glioblastoma: report of two cases. Neurosurgical Review 2004, 27: 281-285. PMID: 15449198, DOI: 10.1007/s10143-004-0346-5.Peer-Reviewed Original ResearchConceptsRing-enhancing lesionsLow-grade lesionsSecond patientMalignant gliomasRight medial temporal lobe lesionInitial MRI evaluationTraditional imaging findingsDe novo lesionsNew-onset seizuresMedial temporal lobe lesionsT2 signal changeRight precentral gyrusTemporal lobe lesionsMedial temporal lesionsRight frontal lesionDe novo glioblastomaEarly MRINovo lesionsNeurological examinationSubsequent resectionImaging findingsFirst patientMRI evaluationTumor suggestiveTemporal lesions
1996
BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines.
Jaworski D, Kelly G, Piepmeier J, Hockfield S. BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Research 1996, 56: 2293-8. PMID: 8625302.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnimalsBiomarkers, TumorBrain NeoplasmsBrevicanCarrier ProteinsChild, PreschoolChondroitin Sulfate ProteoglycansFemaleGliomaHumansHyaluronic AcidIn Situ HybridizationLectins, C-TypeMaleMiddle AgedNeoplasm InvasivenessNeoplasm ProteinsNeoplasm TransplantationNerve Tissue ProteinsRatsRats, Inbred LewRats, Sprague-DawleyTumor Cells, CulturedConceptsGlioma cell linesSurgical samplesIntracranial graftsCell linesAdult human cortexInvasive glioma cell linesBrain metastasesNonglial tumorsNoninvasive cell linesMalignant gliomasExtracellular brainNormal brainTumor invasionHyaluronan-binding proteinHuman cortexGliomasTumorsInvasive behaviorStandard cell culture conditionsGraftBrainBEHABCell culture conditionsSelective markerMetastasisA phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain
Halperin E, Herndon J, Schold S, Brown M, Vick N, Cairncross J, Macdonald D, Gaspar L, Fischer B, Dropcho E, Rosenfeld S, Morowitz R, Piepmeier J, Hait W, Byrne T, Salter M, Imperato J, Khandekar J, Paleologos N, Burger P, Bentel G, Friedman A. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. International Journal Of Radiation Oncology • Biology • Physics 1996, 34: 793-802. PMID: 8598355, DOI: 10.1016/0360-3016(95)02025-x.Peer-Reviewed Original ResearchConceptsExternal beam radiotherapyKarnofsky performance statusMedian survivalSurvival benefitERT groupAnaplastic gliomasBeam radiotherapyMitomycin CVs. 11.4 monthsProportion of patientsSignificant survival benefitPossible survival benefitTreatment of adultsYears of ageBCNU groupPerformance statusProspective trialHistologic diagnosisMalignant gliomasMito groupStereotactic biopsyPatientsGreater riskFourth weekThird day
1990
The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas.
Hait W, Byrne T, Piepmeier J, Durivage H, Choudhury S, Davis C, Gates J. The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas. Cancer Research 1990, 50: 6636-40. PMID: 1698540.Peer-Reviewed Original ResearchConceptsCentral nervous systemClinical trialsNormal brainNervous systemPhase II clinical trialPhase I clinical trialFatal pulmonary toxicityObjective tumor responseTreatment of patientsHigh-grade gliomasComplete responseCombination therapyPulmonary toxicityTumor responseFatal malignancyMalignant gliomasPreclinical modelsPharmacological characteristicsGrade gliomasGlioblastoma multiformePatientsGliomasRat cerebrumCalmodulin inhibitorsBleomycin
1988
Malignant Glioma of the Optic Chiasm Eight Years After Radiotherapy for Prolactinoma
Hufnagel T, Kim J, Lesser R, Miller J, Abrahams J, Piepmeier J, Manuelidis E. Malignant Glioma of the Optic Chiasm Eight Years After Radiotherapy for Prolactinoma. JAMA Ophthalmology 1988, 106: 1701-1705. PMID: 3196211, DOI: 10.1001/archopht.1988.01060140873031.Peer-Reviewed Original Research